Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Neurology and Neuroscience Reports
Published in: Current Neurology and Neuroscience Reports 4/2016

01-04-2016 | Demyelinating Disorders (DN Bourdette and M Cameron, Section Editors)

Vaccines in Multiple Sclerosis

Authors: Eric M. L. Williamson, Salim Chahin, Joseph R. Berger

Published in: Current Neurology and Neuroscience Reports | Issue 4/2016

Login to get access

Abstract

Vaccinations help prevent communicable disease. To be valuable, a vaccine’s ability to prevent disease must exceed the risk of adverse effects from administration. Many vaccines present no risk of infection as they are comprised of killed or non-infectious components while other vaccines consist of live attenuated microorganisms which carry a potential risk of infection—particularly, in patients with compromised immunity. There are several unique considerations with respect to vaccination in the multiple sclerosis (MS) population. First, there has been concern that vaccination may trigger or aggravate the disease. Second, disease-modifying therapies (DMTs) employed in the treatment of MS may increase the risk of infectious complications from vaccines or alter their efficacy. Lastly, in some cases, vaccination strategies may be part of the treatment paradigm in attempts to avoid complications of therapy.
Literature
1.•
Langer-Gould A, Albers KB, Van Den Eeden SK, Nelson LM. Autoimmune diseases prior to the diagnosis of multiple sclerosis: a population-based case-control study. Mult Scler. 2010;16(7):855–61. Recent review of a large health system’s records that failed to reveal any causal association between vaccination and multiple sclerosis or CNS demyelinating disease, further adding credence to 2011 Institute of Medicine Report.CrossRefPubMed
2.
Dore-Duffy P, Donaldson JO, Rothman BL, Zurier RB. Antinuclear antibodies in multiple sclerosis. Arch Neurol. 1982;39(8):504–6.CrossRefPubMed
3.
Singh VK. Detection of antinuclear antibody in the serum of patients with multiple sclerosis. Immunol Lett. 1982;4(6):317–9.CrossRefPubMed
4.
Roussel V, Yi F, Jauberteau MO, Couderq C, Lacombe C, Michelet V, et al. Prevalence and clinical significance of anti-phospholipid antibodies in multiple sclerosis: a study of 89 patients. J Autoimmun. 2000;14(3):259–65.CrossRefPubMed
5.
Mourik J, The TH, Nater JP, Minderhoud JM. Cell-mediated immune reactivity in multiple sclerosis. Neurology. 1981;31(8):1036–8.CrossRefPubMed
6.•
Williamson EM, Berger JR. Infection risk in patients on multiple sclerosis therapeutics. CNS Drugs. 2015;29(3):229–44. Comprehensive review of infections encountered in multiple sclerosis to date, including understanding of how infection may worsen the disease.CrossRefPubMed
7.
Rutschmann OT, McCrory DC, Matchar DB, Immunization Panel of the Multiple Sclerosis Council for Clinical Practice Guidelines. Immunization and MS: a summary of published evidence and recommendations. Neurology. 2002;59(12):1837–43.CrossRefPubMed
8.
Correale J, Fiol M, Gilmore W. The risk of relapses in multiple sclerosis during systemic infections. Neurology. 2006;67(4):652–9.CrossRefPubMed
9.
Buljevac D, Flach HZ, Hop WC, Hijdra D, Laman JD, Savelkoul HF, et al. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain. 2002;125(Pt 5):952–60.CrossRefPubMed
10.•
Loebermann M, Winkelmann A, Hartung HP, Hengel H, Reisinger EC, Zettl UK. Vaccination against infection in patients with multiple sclerosis. Nat Rev Neurol. 2011;8(3):143–51. Another review of vaccinations use in MS, highlights the concern of using live vaccines in concert with immune suppressing agents.CrossRef
11.
Sutton I, Lahoria R, Tan I, Clouston P, Barnett M. CNS demyelination and quadrivalent HPV vaccination. Mult Scler. 2009;15(1):116–9.CrossRefPubMed
12.
Pellegrino P, Carnovale C, Pozzi M, Antoniazzi S, Perrone V, Salvati D, et al. On the relationship between human papilloma virus vaccine and autoimmune diseases. Autoimmun Rev. 2014;13(7):736–41.CrossRefPubMed
13.
Farez MF, Correale J. Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis. Arch Neurol. 2011;68(10):1267–71.CrossRefPubMed
14.
Medicine). IIo. Adverse effects of vaccines: evidence and causality. Washington, DC: The National Academies Press; 2012.
15.
Langer-Gould A, Qian L, Tartof SY, Brara SM, Jacobsen SJ, Beaber BE, et al. Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases. JAMA Neurol. 2014;71(12):1506–13.CrossRefPubMed
16.
Confavreux C, Suissa S, Saddier P, Bourdes V, Vukusic S, Vaccines in Multiple Sclerosis Study Group. Vaccinations and the risk of relapse in multiple sclerosis. N Engl J Med. 2001;344(5):319–26.CrossRefPubMed
17.
De Keyser J. Safety of tetanus vaccination in relapsing-remitting multiple sclerosis. Infection. 1998;26(5):319.CrossRefPubMed
18.
Hernan MA, Alonso A, Hernandez-Diaz S. Tetanus vaccination and risk of multiple sclerosis: a systematic review. Neurology. 2006;67(2):212–5.CrossRefPubMed
19.
20.•
Pellegrino P, Carnovale C, Perrone V, Pozzi M, Antoniazzi S, Radice S, et al. Efficacy of vaccination against influenza in patients with multiple sclerosis: the role of concomitant therapies. Vaccine. 2014;32(37):4730–5. Excellent discussion of the flu vaccine and illustration of the rationale for administering influenza vaccine in patients with MS.CrossRefPubMed
21.
De Keyser J, Zwanikken C, Boon M. Effects of influenza vaccination and influenza illness on exacerbations in multiple sclerosis. J Neurol Sci. 1998;159(1):51–3.CrossRefPubMed
22.
Salvetti M, Pisani A, Bastianello S, Millefiorini E, Buttinelli C, Pozzilli C. Clinical and MRI assessment of disease activity in patients with multiple sclerosis after influenza vaccination. J Neurol. 1995;242(3):143–6.CrossRefPubMed
23.
Michielsens B, Wilms G, Marchal G, Carton H. Serial magnetic resonance imaging studies with paramagnetic contrast medium: assessment of disease activity in patients with multiple sclerosis before and after influenza vaccination. Eur Neurol. 1990;30(5):258–9.CrossRefPubMed
24.
Miller AE, Morgante LA, Buchwald LY, Nutile SM, Coyle PK, Krupp LB, et al. A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis. Neurology. 1997;48(2):312–4.CrossRefPubMed
25.
Michiels B, Govaerts F, Remmen R, Vermeire E, Coenen S. A systematic review of the evidence on the effectiveness and risks of inactivated influenza vaccines in different target groups. Vaccine. 2011;29(49):9159–70.CrossRefPubMed
26.
Olberg HK, Cox RJ, Nostbakken JK, Aarseth JH, Vedeler CA, Myhr K-M. Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study. Multiple Sclerosis J. 2014;20(8):1074–80.CrossRef
27.
Mehling M, Fritz S, Hafner P, Eichin D, Yonekawa T, Klimkait T, et al. Preserved antigen-specific immune response in patients with multiple sclerosis responding to IFNβ-therapy. PLoS ONE. 2013;8(11), e78532.CrossRefPubMedPubMedCentral
28.
Schwid SR, Decker MD, Lopez-Bresnahan M, Rebif-Influenza Vaccine Study Investigators. Immune response to influenza vaccine is maintained in patients with multiple sclerosis receiving interferon beta-1a. Neurology. 2005;65(12):1964–6.CrossRefPubMed
29.
Vågberg M, Kumlin U, Svenningsson A. Humoral immune response to influenza vaccine in natalizumab-treated MS patients. Neurol Res. 2012;34(7):730–3.CrossRefPubMed
30.
Mehling M, Hilbert P, Fritz S, Durovic B, Eichin D, Gasser O, et al. Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients. Ann Neurol. 2011;69(2):408–13.CrossRefPubMed
31.
Boulton C, Meiser K, David OJ, Schmouder R. Pharmacodynamic effects of steady-state fingolimod on antibody response in healthy volunteers: a 4-week, randomized, placebo-controlled, parallel-group, multiple-dose study. Int J Clin Pharmacol. 2012;52(12):1879–90.CrossRef
32.
Kappos L, Mehling M, Arroyo R, Izquierdo G, Selmaj K, Curovic-Perisic V, et al. Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis. Neurology. 2015;84(9):872–9.CrossRefPubMed
33.
Bar-Or A, Freedman MS, Kremenchutzky M, Menguy-Vacheron F, Bauer D, Jodl S, et al. Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis. Neurology. 2013;81(6):552–8.CrossRefPubMedPubMedCentral
34.
Mormile R. Hepatitis B, virus (HBV) infection and multiple sclerosis: one more reason to undergo vaccination? Immunol Lett. 2015;165(1):60–1.CrossRefPubMed
35.
Martínez-Sernández V, Figueiras A. Central nervous system demyelinating diseases and recombinant hepatitis B vaccination: a critical systematic review of scientific production. J Neurol. 2013;260(8):1951–9.CrossRefPubMed
36.
Grimaldi-Bensouda L, Guillemot D, Godeau B, Bénichou J, Lebrun-Frenay C, Papeix C, et al. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects. J Intern Med. 2014;275(4):398–408.CrossRefPubMed
37.
Scheller N, Svanström H, Pasternak B, et al. Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. JAMA. 2015;313(1):54–61.CrossRefPubMed
38.
DeStefano F, Verstraeten T, Jackson LA, Okoro CA, Benson P, Black SB, et al. Vaccinations and risk of central nervous system demyelinating diseases in adults. Arch Neurol. 2003;60(4):504–9.CrossRefPubMed
39.
Kaufman M, Pardo G, Rossman H, Sweetser MT, Forrestal F, Duda P. Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis. J Neurol Sci. 2014;341(1–2):22–7.CrossRefPubMed
40.
McCarthy CL, Tuohy O, Compston DA, Kumararatne DS, Coles AJ, Jones JL. Immune competence after alemtuzumab treatment of multiple sclerosis. Neurology. 2013;81(10):872–6.CrossRefPubMedPubMedCentral
41.
Ahlgren C, Odén A, Torén K, Andersen O. Multiple sclerosis incidence in the era of measles-mumps-rubella mass vaccinations. Acta Neurol Scand. 2009;119(5):313–20.CrossRefPubMed
42.
Ross RT, Nicolle LE, Cheang M. The varicella zoster virus: a pilot trial of a potential therapeutic agent in multiple sclerosis. J Clin Epidemiol. 1997;50(1):63–8.CrossRefPubMed
43.
Farez MF, Correale J. Immunizations and risk of multiple sclerosis: systematic review and meta-analysis. J Neurol. 2011;258(7):1197–206.CrossRefPubMed
44.
Ristori G, Buzzi MG, Sabatini U, Giugni E, Bastianello S, Viselli F, et al. Use of Bacille Calmette-Guerin (BCG) in multiple sclerosis. Neurology. 1999;53(7):1588–9.CrossRefPubMed
45.
Ristori G, Romano S, Cannoni S, Visconti A, Tinelli E, Mendozzi L, et al. Effects of Bacille Calmette-Guerin after the first demyelinating event in the CNS. Neurology. 2014;82(1):41–8.CrossRefPubMedPubMedCentral
46.
Bar-Or A, Wiendl H, Miller B, Benamor M, Truffinet P, Church M, et al. Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens. Neurol Neurophysiol Neurosci. 2015;2(2), e70.
47.
Fragoso YD, Brooks JB, Gomes S, de Oliveira FT, da Gama PD. Report of three cases of herpes zoster during treatment with natalizumab. CNS Neurosci Ther. 2013;19(4):280–1.CrossRefPubMed
48.
Bourdette D, Gilden D. Fingolimod and multiple sclerosis: four cautionary tales. Neurology. 2012;79(19):1942–3.CrossRefPubMed
49.
Bourre B, Lefaucheur R, Ahtoy P, Travers F, Fetter D. Varicella zoster virus acute myelitis in a patient with MS treated with natalizumab. Neurology. 2013;81(22):1966–7.CrossRefPubMed
50.
Yeung J, Cauquil C, Saliou G, Nasser G, Rostomashvili S, Adams D, et al. Varicella zoster virus acute myelitis in a patient with MS treated with natalizumab. Neurology. 2013;80(19):1812–3.CrossRefPubMedPubMedCentral
51.
Novartis. Gilenya [package insert]. Stein SDbNPCEH, New Jersey. Revised August 2015.
52.
Genzyme. Lemtrada [package insert]. Cambridge MG, 2015.
53.
54.
Berger JR. Varicella vaccination after fingolimod: a case report. Mult Scler Relat Disord. 2013;2(4):391–4.CrossRefPubMed
55.
Genzyme. Aubagio prescribing information. Cambridge MG, 2015.
56.
Chahin S, Berger JR. A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy. J Neurovirol. 2014.
Metadata
Title
Vaccines in Multiple Sclerosis
Authors
Eric M. L. Williamson
Salim Chahin
Joseph R. Berger
Publication date
01-04-2016
Publisher
Springer US
Published in
Current Neurology and Neuroscience Reports / Issue 4/2016
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-016-0637-6

Other articles of this Issue 4/2016

Current Neurology and Neuroscience Reports 4/2016 Go to the issue

Movement Disorders (S Fox, Section Editor)

Novel Approaches to Optimization of Levodopa Therapy for Parkinson’s Disease

Neurotrauma (M Kumar, Section Editor)

Cerebral Lactate Metabolism After Traumatic Brain Injury

Neurology of Systemic Diseases (J Biller, Section Editor)

Neurologic Complications of Commonly Used Drugs in the Hospital Setting

Neurotrauma (M Kumar, Section Editor)

Neuroprotection Trials in Traumatic Brain Injury

Demyelinating Disorders (DN Bourdette and M Cameron, Section Editors)

The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis

Movement Disorders (S Fox, Section Editor)

Integrated Approach for Pain Management in Parkinson Disease